HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

JOURNAL ARTICLE published March 2014 in British Journal of Cancer

Authors: Y J Liu | D Shen | X Yin | P Gavine | T Zhang | X Su | P Zhan | Y Xu | J Lv | J Qian | C Liu | Y Sun | Z Qian | J Zhang | Y Gu | X Ni